AstraZeneca’s MedImmune Opens New Cancer R&D Lab
MedImmune, the biologics arm of AstraZeneca, the Cancer Research UK, and its commercial arm, Cancer Research Technology, have opened a new laboratory that will focus on the discovery and development of biologic cancer treatments and diagnostics. Cancer Research Technology is a commercialization and development company and Cancer Research UK is a cancer charity. The new laboratory, the CRUK-MEDI Alliance Laboratory, is located in Granta Park, a science and technology park in Great Abington near Cambridge, England.
Both Cancer Research UK and MedImmune scientists will work together in the laboratory and collaborate to share knowledge and expertise to discover and develop biologics to treat and diagnose cancer. The alliance will bring together MedImmune's human antibody phage display libraries and protein-engineering expertise with Cancer Research UK's cancer biology expertise. Cancer Research UK has provided the equipment and operational funding for the laboratory and will contribute a portfolio of drug targets through its network of principal investigators. MedImmune will manage the drug-discovery process for accepted projects.